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Abstract
Preclinical evaluation of novel cancer agents requires models that accurately reflect the biology and molecular
characteristics of human tumors. Molecular profiles of eight pancreatic ductal adenocarcinoma patient tumors
were compared to corresponding passages of xenografts obtained by grafting tumor fragments into immuno-
compromised mice. Molecular characterization was performed by copy number analysis, gene expression and
microRNA microarrays, mutation analysis, short tandem repeat (STR) profiling, and immunohistochemistry. Xeno-
grafts were found to be highly representative of their respective tumors, with a high degree of genetic stability
observed by STR profiling and mutation analysis. Copy number variation (CNV) profiles of early and late xenograft
passages were similar, with recurrent losses on chromosomes 1p, 3p, 4q, 6, 8p, 9, 10, 11q, 12p, 15q, 17, 18, 20p,
and 21 and gains on 1q, 5p, 8q, 11q, 12q, 13q, 19q, and 20q. Pearson correlations of gene expression profiles of
tumors and xenograft passages were above 0.88 for all models. Gene expression patterns between early and late
passage xenografts were highly stable for each individual model. Changes observed in xenograft passages largely
corresponded to human stromal compartment genes and inflammatory processes. While some differences exist
between the primary tumors and corresponding xenografts, the molecular profiles remain stable after extensive
passaging. Evidence for stability in molecular characteristics after several rounds of passaging lends confidence to
clinical relevance and allows for expansion of models to generate the requisite number of animals required for
cohorts used in drug screening and development studies.
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Introduction
Despite significant efforts, advanced pancreatic adenocarcinoma
remains one of the most lethal cancers. According to the American
Cancer Society 2013 Cancer Facts and Figures report, pancreatic
cancer and liver cancer are the only cancers for which, in both
men and women, incidence and death rates have been increasing
between 2000 and 2009 [1]. Because early-stage pancreatic cancer
is often asymptomatic, a high percentage of patients are not diag-
nosed until the disease has progressed to an advanced stage, making
treatment of the disease highly challenging. Early metastases, difficult
surgical approach/unresectable tumors, and poor response or resis-
tance to current treatment modalities (gemcitabine and/or radio-
therapy) contribute to a poor prognosis for patients with advanced
disease [2]. Novel therapies are urgently needed to improve patient
survival and prognosis over existing therapies.
Preclinical efficacy of novel agents observed in traditional cell line
xenograft models has often not translated to clinical efficacy. The
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inability of conventional xenograft models to reliably predict clinical
efficacy is one of the most frequently cited reasons for the high failure
rate of novel anticancer therapies in oncology clinical trials [3–5].
Well-characterized cell lines used in xenograft models have adapted
to extensive passaging on plastic outside of a natural tumor environ-
ment and lack the human extracellular matrix component that is
critical for cancer cell–stromal cell interactions. Genetic divergence
can occur between a primary tumor and a cell line derived from that
tumor due to differences in selective pressures and genetic stress
encountered in a tumor versus in vitro culture [6]. Models that more
accurately reflect tumor heterogeneity and interaction with the tumor
microenvironment to more accurately reflect tumor complexity and
predict response to therapies in the clinic are needed. This has led
to the development of models by directly engrafting cancer patient–
derived tumor tissues into immunodeficient mice with the aim of
retaining histopathologic features and molecular characteristics of
the original tumor, as reviewed in [7]. A vital question relating to
patient-derived tumor xenografts (PDTXs) is whether tumor charac-
teristics are maintained during passaging. A limited number of studies
have been performed to extensively compare cellular and molecular
characterizations of primary tumors to their corresponding xeno-
grafts [6,8–17].
We report the establishment of a panel of pancreatic ductal
adenocarcinoma PDTX models. We confirmed that the xenografts
are representative of their corresponding original patient tumors
and generated molecular profiles to aid in future preclinical eval-
uation of targeted oncology therapies. While previous studies have
described the establishment and characterization of pancreatic
cancer PDTX models, this is the first study that contains extensive
molecular characterization to compare the genomic profiles of
xenograft models to the original patient tumors they were derived
from, as well as an examination of genomic stability of those mod-
els after extensive passaging. Expanded testing in multiple models
can potentially provide important preclinical translational infor-




Tissue specimens were obtained from pancreatic cancer patient
specimens with their informed consent. The tumor tissue used for
xenograft development was deemed excess to that required for the
patient’s diagnosis and standard of care and treatment. All samples
were anonymized and obtained in accordance with institutional
review boards. Post-surgical pathology reports were provided for
specimens from each patient.
Tissue Sampling
Clinical samples were collected immediately after surgery and
transferred in culture medium on wet ice for engraftment within
24 hours after resection. Upon receipt of tumors, specimens were
subdivided into three portions. One portion was snap frozen in liquid
nitrogen and stored at −80°C for genomic analysis, the second was
fixed in 10% neutral buffered formalin and paraffin embedded for
histopathologic analysis, and the rest of the tumor was cut into pieces
for engraftment in immunocompromised mice. Clinical data for the
patient samples are provided in Table 1.
Histopathology
Histopathologic evaluation was performed on 5-μm hematoxylin
and eosin (H&E)–stained sections of patient tumors and xenograft
passages and examined under a light microscope. Tissue sections
were reviewed by two independent pathologists to compare the path-
ologic features of the xenografts with those of the corresponding
patient tumor.
Engraftment
Animals were kept in a specific pathogen-free environment, in
positive pressure rooms with filtered and humidified air and main-
tained in accordance to the guidelines of the American Association of
Table 1. Patient-Derived Primary Tumors.
Model Age/Sex Pathology Stage/Grade
AG-Panc2 74/F Invasive moderately to poorly differentiated ductal adenocarcinoma (5 cm),
head of pancreas, invasive into duodenum, with local peripancreatic spread;
metastatic carcinoma to two of five peripancreatic lymph nodes
pT3, pN1, pM1
AG-Panc3 78/F Invasive adenocarcinoma (4.5 cm), moderately differentiated of pancreatic origin;
metastatic pancreatic adenocarcinoma involving at least two of
peripancreatic lymph nodes with extension of tumor into perinodal soft tissues
pT3, pN1, pM1
AG-Panc4 76/F Moderately differentiated; tumor size of 3.5 cm;
metastatic adenocarcinoma to four of nine peripancreatic lymph nodes
pT3, pN1, pM1
AG-Panc5 74/F Ductal adenocarcinoma (2.0 cm), moderately well differentiated;
total of 10 benign peripancreatic lymph nodes showing no evidence of
involvement by metastatic carcinoma
pT3, pN1, pM0
AG-Panc6 72/F Pancreatic ductal adenocarcinoma, metastatic moderately differentiated
adenocarcinoma to right abdominal wall
pT3, pN1, pM1
AG-Panc8 62/M Moderately differentiated pancreatic adenocarcinoma in pancreatic head,
greatest dimension: 1.9 cm, tumor invades duodenal wall
pT3, pN1, pMx
AG-Panc9 57/F Poorly differentiated ductal adenocarcinoma of pancreas (pancreatic head)
measuring 3.5 cm in greatest dimension, tumor infiltrates into
peripancreatic fat and duodenal wall, 7 of 19 lymph nodes positive for
metastatic carcinoma
pT3, pN1, pM1
AG-Panc10 69/M Poorly differentiated adenocarcinoma (6.5 cm) in pancreatic head,
tumor extension invades peripancreatic soft tissue and duodenal wall,
5 of 10 lymph nodes positive for metastases
pT3, pN1, pM1
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Laboratory Animal Care. Pancreatic ductal adenocarcinoma (PDA)
tumor specimens from resected patients were reduced into small pieces
(2-3 mm) and implanted subcutaneously in the flanks of imprinting
control region–severe combined immunodeficient (ICR SCID) mice
(Taconic, Germantown, NY) and propagated by serial transplantation.
Dependent on tumor tissue availability, tumor fragments were implanted
in a minimum of five mice (first generation). Five to 10 mice were
monitored for health (body weight) and tumor growth. Mice were
killed, and subcutaneous tumors were aseptically harvested when a
volume of 1000 to 1500 mm3 was reached, following Institutional
Animal Care and Use Committee guidelines. The tumors were sub-
sequently divided into pieces for genomic characterization and histo-
pathologic analysis as described above, as well as subsequent passaging
in mice. Subsequent generations of mice were monitored for health
and tumor growth characteristics as with the first-generation mice.
Xenograft models that failed to develop within 6 months in the first-
generation mice were discontinued. PDTX models were considered
fully established if the following criteria were met: 1) first-generation
growth, 2) greater than 80% tumor take rate at third generation, with
<12 weeks growth rate and stable growth kinetics, and 3) regrowth of
the cryopreserved tumor fragment. Models were passaged beyond the
third generation if necessary to reach stable growth kinetics. Human
origin (%) of the tumors was confirmed at every passage as described
below. For orthotopic models, tumor pieces were either surgically
implanted into the pancreas or digested and injected into the pancreas
as a cell suspension mix (50% vol/vol) with Cultrex. For the AG-Panc2
model, two separate studies were performed by orthotopic implantation
of tumors from subcutaneous passages 10 and 39 from this established
model. For AG-Panc10, the original patient tumor was implanted sub-
cutaneously (p0) and then subsequently implanted both orthotopically
and subcutaneously (p1). The p1 orthotopic tumor was harvested and
subsequently passaged again orthotopically (p2). AG-Panc13 was simi-
lar to AG-Panc10 except that the original patient tumor was implanted
in both subcutaneous and orthotopic location (p0) and subsequently
passaged again orthotopically (p1).
Short Tandem Repeat (STR) Profiling
DNA typing by multiplex polymerase chain reaction (PCR) of
short repetitive elements of highly polymorphic markers was per-
formed to assess genetic stability of xenografts. STR profiling and
analysis was performed using the AmpFISTR Identifiler PCR Ampli-
fication Kit (Applied Biosystems, Foster City, CA).
Mutation Analysis
cDNA synthesized using an oligo(dT) priming method was diluted
1:10 in ddH2O, and 2 μl was then used as a template in PCR. PCR
was performed by double amplification method using primers bind-
ing outside of the protein coding region, with the exception of the
CTNNB1 primers that targeted the frequent single nucleotide poly-
morphism (SNP) region. Gene-specific primers were designed in
Primer3 (Supplementary Data section). PCR was performed in a
mixture of 2 μl of diluted cDNA, 1× high-fidelity PCR buffer, 2 mM
MgSO4, 0.2 mM dNTP, 0.4 μM forward and reverse primers, and
0.004 U Platinum Taq DNA Polymerase High Fidelity (Life Tech-
nologies, Carlsbad, CA) in a total volume of 50 μl with the following
thermocycling parameters: 5 minutes at 94°C, repeated 20 seconds at
94°C, 20 seconds at 58°C, and 40 to 70 seconds at 68°C for 35 cycles.
For the second round of PCR, 1 μl of the first round PCR product was
amplified following the same conditions but with the number of cycles
reduced to 30. PCR products were purified using QiagenMinElute Gel
Extraction Kit following the manufacturer’s protocol. The purified
PCR product was sequenced using ABI Prism 3730 DNA sequencer.
The sequence traces were aligned and analyzed for SNPs using Vector
NTI (Life Technologies).
Whole Exome Sequencing
Whole exome sequencing was performed by Ambry Genetics
(Aliso Viejo, CA). Briefly, 100-bp paired-end libraries were prepared
using the TruSeq DNA Sample Preparation protocol (Illumina,
San Diego, CA) and exome enrichment by SeqCap EZ Exome
Library v3.0 (NimbleGen, Madison, WI). The amplified capture
DNA library size and concentration were determined using an Agilent
Bioanalyzer. Sequencing of libraries was performed on a HiSeq2000
(Illumina) with libraries seeded onto a flow cell at 9 pM/lane. Initial
data processing and base calling, including extraction of cluster
intensities, was done using RTA 1.12.4 (HiSeq Control Software
1.4.5). Sequence quality filtering script was executed in the Illumina
CASAVA software (v1.8.2; Illumina, Hayward, CA). For variant detec-
tion, the paired-end raw reads were aligned to the human reference
genome Build 37 (or hg19) using the Illumina CASAVA 1.8.2 software
on Linux clusters. A single BAM alignment file was saved and used in
SoftGenetics NextGENe v2.2.1 for SNP and indel analysis.
Array Comparative Genomic Hybridization
Labeling, hybridization, and scanning. Genomic DNA (gDNA)
was isolated from xenografts and primary tumors by DNeasy Blood
and Tissue Kit (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions. gDNA was quantified on a NanoDrop ND-
8000, and DNA integrity was verified on agarose gel. For xenograft
specimens, the percentage of mouse and human component was
determined by quantitative PCR (qPCR) measurement of β-actin
using species-specific primers as previously described [18].
On the basis of our previous studies, we excluded samples with
greater than 15% mouse component as candidates for hybridiza-
tion to eliminate confounding analysis due to potentially extensive
cross-hybridization of mouse gDNA. Cy5- and Cy3-labeled gDNA
were prepared using Agilent Genomic DNA Enzymatic Labeling
Kit according to the manufacturer’s instructions. Specifically, 500 ng
of non-amplified gDNA or 2 μg of GenomePlex Complete whole
genome amplified gDNA (Sigma, St Louis, MO) was labeled with
cyanine 5–deoxyuridine triphosphate (dUTP), and an equivalent
amount of reference (gender-matched human normal female or
male DNA; Promega, Madison, WI) was cyanine 3–dUTP labeled.
Each labeled gDNA was purified using an Amicon 30-kDa filter
(EMD Millipore, Billerica, MA) and quantified on a NanoDrop
ND-8000 UV Spectrophotometer using Microarray/DNA-50
measurement. Specific activity of the dyes was calculated in pico-
moles per microgram in which the minimum threshold for cyanine
5 is 20 pmol/μg and the minimum for cyanine 3 is 25 pmol/μg.
The purified labeled gDNA was co-hybridizedto Agilent SurePrint
G3 human CGH (2X400K) microarrays, placed in SureHyb hybrid-
ization chambers, and rotated at 20 rpm for 40 hours in a 65°C
oven. After hybridization, microarray slides were disassembled,
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washed, dried with Stabilization and Drying Solution (Agilent Tech-
nologies, Santa Clara, CA), and covered with an Agilent Ozone-Barrier
Cover. Slides were immediately scanned in an Agilent Microarray
Scanner C using profile Agilent G3_CGH. Images were quantified
using Feature Extraction Software v10.7 (Agilent Technologies).
Data analysis. Feature extraction files from the Agilent 2X400K
aCGH platform were loaded into Partek Genomics Suite v6.6 soft-
ware with recommended normalization settings. Each sample was
compared to the pooled gender-matched reference sample to identify
amplified and deleted regions using a genomic segmentation algo-
rithm within Partek. Segmentation parameters used were given as
follows: signal-to-noise ratio of 0.3, P value of .0001, and the min-
imum number of genomic markers set to five. Unsupervised hierar-
chical clustering and copy number variation (CNV) frequency plots
were performed within Partek Genomics Suite.
Expression Microarray
Labeling, hybridization, and scanning. Total RNA from patient
tumors and two corresponding xenograft passages for each model
were used for expression profiling. Tumor and xenograft samples
were normalized against total RNA from normal pancreas obtained
from two separate sources (Agilent Technologies and Clontech,
Mountain View, CA). Total RNA from xenografts was assessed
for mouse and human components using species-specific primers
for β-actin (Supplementary Data section) before labeling. Cyanine
3–CTP-labeled cRNA target was prepared using One-Color Low
Input Quick Amp Kit and One-Color Spike-In Kit (Agilent Tech-
nologies) using 200 ng of input RNA [RNA integrity number (RIN)
> 8.0] according to the manufacturer’s protocols. Labeled cRNA was
purified using RNeasy Mini Kit (Qiagen) according to the manu-
facturer’s recommendation and was quantified on a NanoDrop
ND-8000 UV Spectrophotometer using Microarray/RNA-40 mea-
surement. Specific activity of cyanine 3 was calculated in picomoles
per microgram with a minimum threshold of 15 pmol/μg.
Labeled cRNA (600 ng) was fragmented by incubation with 5 μl
of 10× blocking reagent and 1 μl of 25× fragmentation buffer in a
25-μl reaction volume for 30 minutes at 65°C. Twenty-five micro-
liters of 2× GE Hybridization Buffer Hi-RPM was added to frag-
mented cRNA and hybridization mix and placed onto Agilent
Human GE 8X60K v2 microarrays. Hybridization was carried out
for 17 hours at 65°C by rotating at 10 rpm. Microarray slides were
washed in GEWash Buffer 1 for 2 minutes and pre-warmed GEWash
Buffer 2 for 2 minutes at room temperature. Microarray slides were
scanned in an Agilent Scanner using profile AgilentHD_GX_1Color
at Green PMT 100%. The scanned image was extracted to data using
Agilent Feature Extraction Software v10.7.
Data analysis. Data analysis was performed, and gene lists were
generated in Partek Genomics Suite v6.6 using the following param-
eters: third quantile normalization, analysis of variance P value < .05,
and fold change ≥ 2.0. Probes with a signal lower than 50 in 100%
of arrays were filtered out. Gene ontology analysis was performed to
gene ontology sets of MSigDB v3.8, which had more than 50 genes
in the gene set, applying Fisher exact test.
MicroRNA Microarray
Labeling, hybridization, and scanning. Total RNA was extracted
using TRIzol and was cleaned up using miRNeasy Micro Kit (Qiagen)
according to the manufacturer’s protocol. RNA was analyzed on RNA-
nano chip (Agilent Technologies). Samples with RIN < 7.0 were not
used. Total RNA (100 ng) was labeled with cyanine 3–pCp using
miRNA Complete Labeling Kit (Agilent Technologies) according
to the manufacturer’s protocol. Two normal pancreas samples were
used for comparison (Clontech and Stratagene). Labeled RNA was
hybridized to SurePrint G3 Human miRNA v16 (8X60K) micro-
arrays (Agilent Technologies), placed in SureHyb hybridization
chambers, and rotated at 20 rpm for 22 hours in a 55°C oven. After
hybridization, microarrays were washed and immediately scanned in
an Agilent Microarray Scanner C using profile Agilent G3_miRNA.
Images were quantified using Feature Extraction Software v10.7
(Agilent Technologies).
Data analysis. Data analysis was performed, and gene lists were
generated in Partek Genomics Suite v6.6 using the following param-
eters: no normalization, analysis of variance P value < .01, and fold
change ≥ 2.0. Probes with a signal lower than 2 in 100% of arrays
were filtered out.
qPCR Analysis
RNA expression. Primers used in qPCR are described in the
Supplementary Data section. Reactions were performed in triplicate
in a 5-μl reaction volume containing 0.5 μl of diluted cDNA based
on normalization factor, SsoFast EvaGreen (Bio-Rad, Hercules, CA),
and 400 μM of gene-specific forward and reverse primers. qPCR was
carried out on a CFX384 Real-Time PCR machine (Bio-Rad)
according to the following thermocycling parameters: 2 minutes
at 95°C, repeated 5 seconds at 95°C and 5 seconds at 58°C (col-
lected SYBR signal) for 40 cycles. Melting curves were generated
from 65 to 95°C by collecting SYBR signal every 2°C for 3 seconds.
C t values and melting curves were determined in CFX Manager v1.5
(Bio-Rad). Relative gene expression was calculated by normalization
to glyceraldehyde-3-phosphate dehydrogenase (GADPH) using the
2−ΔΔCt method [19].
CNV analysis. Human-specific qPCR copy number assays (qBio-
marker Copy Number PCR Assays) were purchased from Qiagen.
Normalization of input DNA used a human multicopy reference
assay (Qiagen). Reactions were performed in triplicate in a 10-μl
reaction volume containing 1× final volume of qBiomarker SYBR
ROX FAST mastermix (Qiagen), 2 ng of gDNA, and 0.5 μl of qBio-
marker copy number PCR assay (Qiagen). qPCR was carried out in a
CFX Real-Time PCRmachine (Bio-Rad) using the following thermo-
cycling parameters: 10 minutes at 95°C, repeated 15 seconds at 95°C
and 1 minute at 60°C (collected SYBR signal) for 40 cycles at a
reduced ramp rate of 1°C/s. Melting curves were generated from 65
to 95°C by collecting SYBR signal every 2°C for 3 seconds. C t values
and melting curves were determined using CFX Manager software
v2.1. Gene copy number was calculated using the calibrator genome
method in which the calibrator was a normal pancreas sample and is
assumed to have a normal diploid genome. The predicted gene of
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interest (GOI) copy number in a test sample is given by the following





A total of 12 primary tumors obtained from surgery were implanted
subcutaneously into SCID mice as described in the Materials and
Methods section. The histopathologic and clinical characteristics of
the patient’s primary tumors that successfully engrafted are displayed
in Table 1. Histologically, all the tumors were pancreatic ductal adeno-
carcinomas, which were moderately to poorly differentiated. Metastases
were detected in a majority of the patients, but only primary tumors
were implanted in this study. Of the 12 patient tumors that were
implanted, 8 were established as xenografts for an engraftment rate of
66.7%, which is consistent with a previous study using pancreatic
tumors [10].
Growth rates to reach a tumor volume of 1000 mm3 ranged from
4 to 12 weeks, depending on the model and passage number. Xeno-
grafts have been propagated for a minimum of five passages, with
some models having been extensively passaged (>30 passages). Histo-
pathology comparisons between patient’s primary tumors and xeno-
graft passages were performed. Tissue sections stained for cytokeratin
18 and H&E showed that the respective models retained the original
morphology of the human primary tumor (Figure 1). The relative
state of differentiation is also retained upon passaging, including
the retention of atypical glandular structures. As is typical of pan-
creatic adenocarcinoma tumors, a high degree of stroma is observed
in the primary tumors. Human stroma is eventually replaced with
murine stroma during successive passaging of the tumors within mice.
A fair degree of stroma is retained throughout passaging but does
appear to decrease somewhat in comparison to that observed in the
primary tumors.
STR Profiling
gDNA from primary tumors and at least one corresponding xeno-
graft passage was isolated and analyzed for the presence of short
tandem repeats at 16 different loci (Table W1). Complete concor-
dance was observed for models AG-Panc2 though 6 at all 16 loci.
AG-Panc9 showed minor differences in two loci, whereas AG-Panc8
and AG-Panc10 showed differences at four loci. Chromosomal loss
or deletions within the Y chromosome was observed in AG-Panc8
xenografts but not in the original tumor by STR profiling; however,
array comparative genomic hybridization (aCGH) profiling does
show loss in the original tumor. The discrepancy may be explained
in part by loss of stroma or enrichment of tumor during passaging.
We have similar observations for other xenograft models across
various cancer indications that we have developed. Loss of the Y
chromosome has also been observed in a number of patient tumors
in various cancer types [20–22]. Overall, genetic identity appears to
have been highly preserved upon passaging.
SNP/Mutation Analysis
Tumors andmatched xenograft passages were analyzed for mutations/
SNPs by Sanger sequencing in a small panel of genes known to be fre-
quently mutated in pancreatic cancer according to the COSMIC data-
base (KRAS, CTNNB1, TP53, and SMAD4). Results of mutational
analysis are shown in Table 2A. Mutations in KRAS were observed at
codon 12 (G12D/R/V) for all samples except AG-Panc5. No KRAS
codon 13 variants were identified. Mixtures of wild-type and mutant
sequences suggest heterogeneity within the tumors. Mutations seen in
the original tumor were conserved in subsequent passages, with the
exception of AG-Panc4. It is possible that the mutation was present
but below the level of detection by Sanger sequencing. The P72R variant
of TP53 was observed in most models, while the R175H mutation
was seen in only AG-Panc4, and H179R variants were observed in
AG-Panc6 and 8. Some SNPs were identified in SMAD4, but no well-
known mutations were identified in either SMAD4 or CTNNB1 in
Figure 1. Immunohistochemical analysis of original patient tumor and xenograft passages for two selected models. Tumor sections
from two different patient tumors and corresponding xenograft passages were stained for H&E and cytokeratin 18.
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any of the models. Overall, the data suggest a high degree of genetic
stability even after 39 passages. From this small panel of genes, we
did not observe evidence for the generation of additional mutations
upon subsequent passaging. Mutations seen in early passages were
maintained and no new mutations were identified. Analysis performed
on a larger panel of genes using qPCR-based assays for specific SNPs
yielded similar results.
We analyzed whole exome sequencing data on these models to
identify cancer gene mutations contained within one or more next-
generation sequencing (NGS) cancer gene sequencing panels from
various vendors or in the Federal Drug Administration absorption,
distribution, metabolism, excretion (ADME) core gene panel to iden-
tify mutations in genes involved in drug metabolism and transport.
Mutations identified among the models included M541L mutations
Table 2. Variant Analysis of Patient Tumors and Xenografts.
(A) Cancer Gene Sequence Analysis
Model Passage KRAS TP53 SMAD4 CTNNB1 KIT ATM APC Detection Method
AG-Panc2 T WT\G12V WT\P72R WT WT ND Sanger
AG-Panc2 P1 G12V P72R R135G WT WT Sanger, qPCR
AG-Panc2 P39 G12V P72R R135G WT WT Sanger, qPCR, WES
AG-Panc3 T WT\G12D P72R WT WT ND Sanger
AG-Panc3 P0 WT\G12D P72R WT WT M541L Sanger, qPCR
AG-Panc3 P34 WT\G12D P72R WT WT M541L E1317Q Sanger, qPCR, WES
AG-Panc4 T WT P72R, WT/R175H WT WT ND Sanger
AG-Panc4 P0 WT\G12R P72R, WT/R175H WT WT WT Sanger, qPCR
AG-Panc4 P22 WT\G12R P72R, R175H WT WT WT Sanger, qPCR, WES
AG-Panc5 T WT WT WT WT ND Sanger
AG-Panc5 P1 WT WT WT WT WT Sanger, qPCR
AG-Panc5 P16 WT WT WT WT WT Sanger, qPCR, WES
AG-Panc6 T WT\G12R P72R, WT/H179R WT WT M541L Sanger, qPCR, WES
AG-Panc6 P1 WT\G12R P72R, H179R WT WT ND Sanger
AG-Panc6 P7 WT\G12R P72R, H179R WT WT ND Sanger
AG-Panc8 T WT\G12D P72R, WT/H179R WT WT WT A1309T Sanger, qPCR, WES
AG-Panc8 P1 WT\G12D P72R, H179R R135*/WT WT ND Sanger
AG-Panc8 P5 WT\G12D P72R, H179R R135* WT ND Sanger
AG-Panc9 T WT\G12V P72R WT WT WT Sanger, qPCR, WES
AG-Panc9 P2 WT\G12V P72R Q169* WT ND Sanger
AG-Panc9 P4 WT\G12V P72R Q169* WT ND Sanger
AG-Panc10 T WT\G12R WT WT WT WT Sanger, qPCR, WES
AG-Panc10 P4 WT\G12R WT WT WT ND Sanger
(B) ADME Core Gene Panel Variants Detected by WES
Gene Variant AG-Panc2 AG-Panc3 AG-Panc4 AG-Panc5 AG-Panc6 AG-Panc8 AG-Panc9 AG-Panc10
ABCC2 rs717620 X
V417I X X X
CYP1A1 I462V X
CYP1A2 rs762551 X X X X X
ABCG2 Q141K X
CYP2B6 R22C X




CYP3A4 rs2242480 X X
GSTP1 I105V X X X X X X
A114 X X X
NAT1 V149I X
S214A X
NAT2 I114T X X X
R197Q X X X
SLC15A2 L350F X X X X
P409S X X X X
R509K X X X X
SLC22A1 M408V X X X X X X X
M420del X X X
SLC22A2 S270A X X X X X X X
SLCO1B1 N130D X X X
V174A X
SLCO1B3 S112A X X X X X X
M233I X X X X X X X X
SULT1A1 R213H X X X X
V223M X X X X X X X X
TPMT A154T X
Y240C X
T, original patient tumor; WT, wild type; ND, not determined, sample not analyzed; WES, whole exome sequencing.
*Stop codon.
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in v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene (KIT) for
AG-Panc3 and 6, A1309T mutation in ataxia telangiectasia mutated
transcript (ATM) for AG-Panc8, and E1317Q mutation in adeno-
matous polyposis coli (APC) for AG-Panc3. Additional variants were
found within ADME genes involved in functions such as transport,
P450 enzymes, and xenobiotic metabolism (Table 2B).
Copy Number Variation Analysis
High-density 400K oligonucleotide arrays were used to investi-
gate chromosomal aberrations within tumor samples. All tumors
were normalized to sex-matched human reference gDNA. Heat
maps of the genome-wide aCGH profiles demonstrated that
AG-Panc2, 3, 4, and 10 showed more extensive chromosomal
abnormalities and intense CNV changes at specific loci (Figure 2A).
Available clinical annotation did not explain this pattern as majority
of the samples are fairly similar in terms of histopathology and tu-
mor/stage grading. It is interesting to note that these four models have
faster growth rates than the other models (data not shown). Similar to
previously published pancreatic cancer studies, recurrent chromosomal
abnormalities included losses on chromosomes 1p, 3p, 4q, 6, 8p, 9, 10,
11q, 12p, 15q, 17, 18, 20p, and 21 and gains on 1q, 5p, 8q, 11q, 12q,
13q, 19q, and 20q (Figure 2B) [23–26].
We were unable to do a comparative analysis of the original
tumors versus xenograft passages due to limiting amounts of patient
tumor tissue and technical limitations. We have determined that
mouse gDNA can cross-hybridize to the human aCGH arrays due
to extensive sequence homology between the two species (Figure W1).
As a result, xenograft tumors with greater than 15% mouse component
were not run on aCGH arrays to avoid confounding signals. As such,
observed differences can either be real changes (clonal enrichment or
de novo acquisition) or changes attributed to technical source of variation
including species cross-hybridization, differences in dilution by stromal
component, or sampling effects. In patient tumors, copy number varia-
tions in tumor cells can be masked by normal or heterogeneous cell
populations within the sample. In xenografted tumors, the same is true,
with the additional complication of replacement of human stroma with
mouse stroma. Loss of human signal and potential contributions of
mouse signal due to cross-hybridization can confound the actual copy
number ratio observed. Application of laser capture microdissection
on sections of the original patient tumor and subsequent xenograft
passages to specifically isolate tumor cells is one possible approach for
addressing this issue, though this is also subject to a sampling effect.
Unfortunately, original patient tissue was limiting and was not in suf-
ficient size to be processed by laser capture microdissection for the
majority of the pancreatic tumors. Alternatively, future studies em-
ploying DNA content–based flow sorting by ploidy may allow for
enrichment of distinct clonal populations or enrichment of tumor cells
within xenograft passages, thereby addressing potential issues related to
sampling bias or isolation based on morphology alone.
CNV stability was studied across xenograft passages by aCGH.
Two late passages each of AG-Panc2, 3, and 4 were screened. All
Figure 2. Copy number variation analysis performed by aCGH. (A) Heatmap and clustering analysis of original tumor samples. (B) Karyogram
of frequency of chromosomal aberrations. (C) Heat map of copy number variation in tumor xenograft passages. Red, amplifications (gains);
blue, deletions (losses).
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samples were confirmed to contain less than 15% mouse component.
Heat maps of the aCGH profiles show nearly identical profiles, sug-
gesting a very high degree of stability during passaging (Figure 2C ).
Likewise, qPCR-based copy number analysis of a small selected panel
of genes was carried out using human-specific qPCR probes.
SMAD4, MYC, and CDKN2A showed high degree of stability dur-
ing passaging, with most of the models harboring SMAD4 and
CDKN2A deletions (Figure 3). SMAD4 mutant pancreatic adeno-
carcinomas have been previously found to have higher metastatic
potential, and the gene was found to be more frequently deleted in
pancreatic tumors that successfully engrafted compared to those that
did not engraft [10,27]. MYC amplification, which is commonly
observed in pancreatic cancer, was observed in three of the models.
Mouse gDNA was not detected by any of the assays, demonstrating
species specificity.
Expression Profiling
Gene expression analysis was carried out on the original patient
tumors and two passages of each of the models (early and late) to
assess the potential for genomic drift over time in vivo. Unsupervised
hierarchical clustering analysis showed that all of the patient tumors
cluster together and the xenografted tumors are contained within the
second cluster (Figure 4, A and B). Microarray profiling was not per-
formed on AG-Panc3 due to poor RNA quality. The two passages
from each xenograft model cluster together, demonstrating that pas-
sages within models are highly similar. While the clustering analysis
of samples on a subset of genes suggests differences between original
tumors and their respective xenograft passages, Pearson correlation
analysis of genome-wide expression shows very high similarity. All
passages compared to their respective original patient tumor had cor-
relations of 0.88 and above (Figure W2). Calculation of significant
gene lists [fold-change (FC) ≥ 2.0 and false discovery rate (FDR) <
0.05] for each model demonstrated that the patient tumors shared
69% to 77% of significantly regulated genes with both xenograft
passages (Figures W2–W3). In addition, we compared the gene
expression profiles of tumors passaged in a subcutaneous or ortho-
topic location by whole genome microarray for three separate models
(Figure 5). The expression profiles between orthotopic and subcuta-
neous tumors were nearly identical in each of the three models. In
comparing the overlap of significant gene lists, AG-Panc2 p6 had
61% to 63% overlap with its corresponding orthotopic tumors,
Figure 3. CNV analysis of SMAD4, MYC, and CDKN2A in xenograft
passages measured by qPCR. Two different passages for each
model were measured for copy number and normalized to either a
pooled normal reference gDNA sample or normal pancreas gDNA.
Gray, normal copynumber; blue, deletion/loss; red, amplification/gain.
Figure 4. Comparison of gene expression profiles between original patient tumors and xenograft passages. (A) Unsupervised hierar-
chical clustering of tumor and xenograft passages. (B) Heat map of gene expression profiles (5915 probes) of original patient tumors and
early and late xenograft passages.
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Figure 5. Comparison of gene expression profiles between original patient tumors, subcutaneous xenografts, and orthotopic xenografts
is shown. Unsupervised hierarchical clustering and heat maps of tumor and subcutaneous/orthotopic xenograft gene expression pro-
files are also shown.
Figure 6. Gene signature panel comparisons between primary tumors and xenograft passages. Comparison of primary tumor (T) versus
xenograft passages (X) shows down-regulation in xenografts of several genes in both a stromal signature and a lymphocyte signature.
Comparison across a metastatic adenocarcinoma signature demonstrated that xenografts were enriched in the metastatic gene signature.
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AG-Panc10 p4 had 71% overlap, and AG-Panc13 p0 had 79% over-
lap with its corresponding p0 orthotopic tumor (Figures W2–
W3). Pearson correlation analysis to compare overall genomic expres-
sion profiles did not reveal any notable differences (Figure W2).
AG-Panc2 subcutaneous passages p6 and p17 had Pearson correlations
ranging from 0.92 to 0.96 with the orthotopic tumors, AG-Panc10
p4 had correlations of 0.97 to 0.98, and AG-Panc13 p0 subcutaneous
tumor had correlations of 0.97 and 0.98 with the p0 and p1 orthotopic
passages of the same tumor.
Differences observed are likely due to changes in tumor micro-
environment resulting from engraftment in immunocompromised
mice. Evidence for this was observed upon examining both a pancreatic
cancer stromal gene set [28,29] and a lymphocyte gene signature [30].
When comparing the original tumors to their xenograft passages, a
large percentage of the genes are upregulated in patient tumors com-
pared to normal pancreas, whereas expression is decreased in cor-
responding xenograft passages (Figure 6). We also examined the
presence of a metastasis-associated gene signature [31] that contains
17 genes identified by comparing adenocarcinoma metastases from
multiple tumor types to unmatched primary adenocarcinomas. In this
analysis, we used the gene expression profiles from eight primary
tumors and two different passages of their matching xenografts.
Five of eight genes were also upregulated in xenografts compared to
counterpart primary tumors, and six of nine genes were downregulated
in a majority of the models. This is consistent with similar observations
by Garrido-Laguna et al. [10] of the presence of a metastatic gene
signature that may contribute to establishment of patient-derived
pancreatic adenocarcinoma xenograft models. Gene ontology analysis
was also performed to identify functional processes altered in xenografts
(Table W2). Functional categories of note for downregulated genes in
xenografts included many immunologic categories (immune response,
inflammatory response, regulation of immune response, and defense
response). Upregulated genes in xenografts included functional groups
related to growth and proliferation (mitotic cell cycle, cell division, cell
cycle, G1/S transition, and cell proliferation). Our results strongly
suggest that differences in gene expression are largely attributed to loss
of human stromal component, loss of tumor-infiltrating lymphocytes,
and decreased inflammatory/immune components within the tumor
microenvironment as a result of engraftment and less dependent on
the location of tumor implantation.
MicroRNA Profiling
Profiling of microRNA expression was performed on original
patient tumors. Due to high homology of many mouse microRNA
sequences, we did not profile xenografted tumors. MicroRNAs with
significantly differential expression in pancreatic tumors versus an
average of two normal pancreas samples were identified (Table W3).
While our sample set of normal and tumor samples is small, we found
a number of microRNAs to be differentially expressed in pancreatic
adenocarcinoma, with up-regulation of miR-10a, 10b, 21, 23a, 23b,
100, 103, 107, 125a, 125b, 143, 146, 155, 181b, 199a, 221, and
223 and down-regulation of miR-148a.We observed very fewmiRNAs
that were downregulated in pancreatic cancer. These results are con-
sistent with previously published studies [32–38].
Discussion
As individualized targeted therapy approaches have become more
common in cancer drug development, models that reflect patient
heterogeneity and more faithfully recapitulate in vivo tumor biology
are essential to improving prediction of clinical efficacy of novel
therapies. The advantages of PDTX models over cell line xenograft
models are many; however, many questions regarding the potential
for histologic, stromal, or genetic drift of xenografts from the primary
tumor have been raised. While methods for establishing PDTX models
have been in place for several decades, only within the last couple of
years have there been studies describing extensive characterization of
such models, made possible by high-throughput genomic technologies.
We have established a number of PDTX models across a number of
cancer indications for the purposes of preclinical drug evaluation in
models that more accurately reflect tumor biology and heterogeneity.
In the present study, we report a detailed molecular characterization of
a panel of eight pancreatic adenocarcinoma PDTXmodels developed in
our laboratory. To determine how histologically representative and
molecularly relevant the xenograft models are, we compared a number
of histologic and genomic/genetic features to the corresponding original
patient tumors.
Morphologically, the xenografts resemble the primary tumors. As
has been described previously, tumor architecture and stromal con-
tent is still present [10,15,17]. Although we have not evaluated this
extensively, the desmoplastic reaction seems less pronounced in xeno-
grafts than in patient tumors. However, we have observed fluctuations
in the degree of stromal content, as well as overall mouse/human
content, from passage to passage. Future studies are needed to evalu-
ate this more extensively and to determine how differences in the
degree of stroma or desmoplastic reaction in xenografts compared
to that observed in the clinical setting can potentially impact drug
efficacy evaluations. Of importance to note, tumor morphology in
PDTX models is more accurately recapitulated than in xenografts
generated by injection of cancer cell lines.
We did not observe the presence of metastases with the PDTX
models described in this study since they were passaged subcutaneously.
We did observe that all eight models that were successfully established
had SMAD4 deletions and that the xenograft passages had a similar
metastasis-associated gene signature seen in a previous study [10]. Pre-
vious publications have demonstrated metastases in pancreatic adeno-
carcinoma PDTX models passaged orthotopically [15,39]. While
orthotopic growth is advantageous in that it more closely resembles
in vivo conditions, routine establishment of such models is more labor
intensive and technically challenging. However, we appreciate that a
combination of different types of models (subcutaneous, orthotopic,
genetically modified mouse models) may be needed to adequately
address specific biologic questions that may arise in the course of
evaluating the preclinical efficacy of novel therapies to increase the
level of confidence that observed efficacy in preclinical models will
translate to clinical efficacy. We examined the ability to take tumors
established in a subcutaneous manner and then subsequently grown
orthotopically when the need arises. Upon resection, the pathology re-
ports for all three patient tumors indicated localized metastatic invasion
to structures such as the lymph nodes, duodenum, and abdominal wall.
Dissemination patterns observed when tumors were grown orthoto-
pically were consistent with this pattern, with no metastases found in
the lung.
Genome-wide examination of genomic stability and RNA expression
levels confirmed that xenografts were highly stable during passaging,
with the greatest differences observed between the primary tumor and
xenograft. In our aCGH analysis, differences in CNV profiles between
primary tumors and xenograft passages were present in the limited
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number of models examined. The potential for cross-hybridization of
mouse gDNA on our platform and other technical factors such as
sampling effects confound the ability to determine whether the differ-
ences observed are due to technical factors or true biologic differences.
Reports in the literature are mixed, with similar CNV profiles observed
in some xenografts and marked differences in others. Using a bacterial
artificial chromosome (BAC) aCGH platform, Reyal et al. [16] re-
ported CNV Pearson correlations of breast tumor/xenograft pairs rang-
ing from 0.23 to 0.87 with 14 of 18 models above 0.50. In a separate
study on breast cancer PDTX models using the Affymetrix SNP 6.0
platform, a higher degree of correlation was observed [9]. However,
within individual models there were loci observed with a greater con-
cordance among xenograft passages than between passaged and fresh
specimens. The degree of similarity observed may be tumor type–
dependent and reflective of differences in tumor biology, stromal
involvement, and role of tumor microenvironment in different cancers.
Alternatively, differences may be a reflection of expansion of subclonal
populations within the original tumor due to selective pressures.
In a panel of colon xenograft models, clustering separated tumors
from xenografts, but no major differences between early and late
passages were observed [11]. In pancreatic cancer PDTX models,
Monsma et al. [14] observed Pearson correlations of 0.92 between
xenograft and patient tumors and 0.97 for melanoma models,
suggesting that differences may be dependent on tumor type. Cor-
relations among different xenograft passages within any particular
model ranged from 0.98 to 0.99 across a wide range of tumor types,
with the largest differences seen between patient tumors to first gen-
eration. Expression profiles between orthotopic and subcutaneous
tumors were nearly identical in each of the three models. While over-
all gene expression profiles were not altered in relation to the site of
tumor growth, we recognize that metastatic potential, interaction
with the microenvironment, drug accessibility, and tumor vascula-
ture are different in tumors grown orthotopically compared to a sub-
cutaneous environment. Further studies would be needed to address
establishment rates between subcutaneous and orthotopic growth.
Nonetheless, our results indicate that switching from subcutaneous
growth to orthotopic growth allows for testing in a more clinically
relevant model with negligible impacts on the global expression pro-
files and that the majority of differences appear to be related to
growth in an immunocompromised murine host rather than the site
of tumor implantation. Overall, the results of our study and existing
reports demonstrate that the majority of the genomic profile of the
original tumor is conserved upon passaging. This in combination
with the absence of genetic drift and preservation of histologic integ-
rity after several generations supports confidence in the clinical rele-
vance of PDTX models.
Gene ontology (GO) analysis to examine phenotypic changes
observed in xenografts yielded similar results to previous studies.
Enrichment for downregulated genes involved in immune response,
extracellular matrix (ECM), and stroma-related genes has been
observed in breast cancer xenografts [8], colon [11], and across a panel
of multiple tumor types [14]. Such results are not unexpected and are
reflective of a combination of decrease of stromal content, replace-
ment of human stroma with murine stroma, down-regulation of
immune responses to enable engraftment and growth in an immuno-
compromised host, and loss of human infiltrating immune cells after
transplantation. Upregulated genes in xenografts were enriched in
processes related to cellular growth and proliferation. Similar enrich-
ment in canonical pathways driving tumorigenesis has been observed
[14]. The observed decreases in immune response coupled with a
metastasis-associated gene signature and up-regulation in proliferative
processes support establishment and maintenance of xenograft in the
immunocompromised host.
Current personalized medicine approaches have been incorporat-
ing next-generation sequencing technologies for genomic profiling of
patient tumors to identify potential therapeutic targets. Sufficient
amounts of gDNA or RNA from the original patient tumors was lim-
ited or not available for some of the models in this study, allowing for
only a comparative analysis between the original tumors and sub-
sequent xenografts on a selected subset of genes by Sanger sequenc-
ing. However, qPCR-based SNP assays and whole exome sequencing
was performed on at least one passage for each model to aid in initial
model selection or to provide information for translational studies in
regard to explaining drug sensitivity/resistance. Liang et al. [40] recently
described genome-wide characterization of three pancreatic adeno-
carcinoma patient tumors using whole genome sequencing and RNA-
Seq. The combination of our gene expression profiling, CNV analysis,
and mutational analysis/whole exome sequencing yielded similar
aberrations in the KRAS pathway and gene alterations commonly
observed in pancreatic adenocarcinoma: frequent mutations in KRAS;
common SMAD4 and CDKN2A deletions; mutations in TP53, KIT,
and ATM; amplification of MYC; and up-regulation of genes involved
in cell cycling and cell division. In addition, we identified a number of
ADME gene variants of interest within our models that may influence
drug resistance, efficacy, or toxicity or have been found to be potential
risk factors for various cancers. In a study of patients with small cell
lung cancer, SNP rs717620 in ABCC2 was moderately associated
with poor response to chemotherapy but strongly associated with
progression-free survival and overall survival [41]. Patients with non-
small cell lung cancer (NSCLC) with the Q141K variant in ABCG2
treated with gefitinib had a four to five times higher risk of diarrhea [42].
This variant was also found to be associated with longer progression-
free survival (PFS) in epithelial ovarian/primary peritoneal cancer fol-
lowing platinum + taxane–based chemotherapy [43]. ABCG2 was also
found to be involved in erlotinib transport, although it is unknown if
this particular variant impacts that function [44]. The P450 enzymes
CYP2C8 and CYP2C9 have well-known involvement in warfarin and
non-steroidal anti-inflammatory drug (NSAID) metabolism and are
also involved in paclitaxel metabolism. In a recent study, the K399R
variant in CYP2C8 was found to be associated with an increased risk
of paclitaxel-induced neuropathy in patients with breast cancer [45].
SLCO1B1/OATP1B1 regulates the uptake of numerous drugs includ-
ing statins and methotrexate. The V174A variant in SLCO1B1 was
found to cause higher plasma concentrations of SN-38, the active
metabolite of irinotecan, in patients with NSCLC, and a higher fre-
quency of grade 4 neutropenia [46]. The I105V variant in GSTP1
was associated with a higher doxorubicin response in patients with
breast cancer [47], whereas the M420del in SLC22A2 SNP was found
to impair imatinib uptake and may modify clinical outcome in patients
with chronic myelogenous leukemia (CML) treated with imatinib [48].
With the aid of sequence analysis, we identified specific oncogenic
mutations that may be driving the biology of the individual tumor
models; however we have also identified mutations/SNPs in genes
involved in drug metabolism and transport that may equally be as
important in determining the sensitivity, resistance, or toxicity of a
novel therapeutic.
Novel effective treatment options remain a critical challenge in
pancreatic cancer. This highly drug-resistant malignancy would
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benefit from predictive markers to define tailored treatment regimens
and response prediction for individualized therapy according to the
molecular profile of individual tumors. Recent studies have applied
DNA content–based flow sorting to isolate clonal populations based
on ploidy to isolate tumor cells from normal cells and enrich for mul-
tiple distinct tumor cell populations [49–51], allowing for a better
understanding of the clonal evolution of pancreatic cancer and other
solid tumors in response to therapies. These studies have demonstrated
that distinct clonal populations of cells within a tumor may not contain
a given therapeutic target of interest or be selected for during the evo-
lution of resistance to targeted therapies. Alternatively, clonal popula-
tions may contain alterations in genes involved in drug metabolism and
transport that may also impact drug efficacy. Future application of such
techniques in conjunction with PDTX models would enhance pre-
clinical drug evaluation through a better ability to determine the clinical
context of each model and identification of aberrations that may either
influence sensitivity/resistance or arise in response to therapy.
Currently, there is a lack of consensus in the field regarding the
extent of passaging optimal for usage of PDTX models in drug eval-
uation. Concern for minimizing the potential for genetic drift has
resulted in a common practice of restricting to 10 or fewer passages.
Conservative approaches that stop further propagation after deter-
mination of successful engraftment may result in as few as two to
three passages. While this minimizes potential for genetic drift, it
becomes a finite resource due to the limited number of mice that
can be implanted within two rounds of passaging. More extensive
passaging allows for larger frozen stocks that are amenable to larger
studies or repeated studies at the same passage number that would be
required in industry-scale preclinical drug evaluation. Depending on
the model, it may take several rounds of passaging to either achieve a
more stable growth rate or one that is more amenable to drug screening.
The largest source of variation from the primary tumor occurs within
the initial passage as a result of engraftment. On the basis of the high
degree of stability observed after successful engraftment and successive
passaging, use of extensively passaged PDTX models appears justified.
A thorough molecular understanding of PDTX models, at any passage
number, is warranted to guarantee clinical relevance and ascertain the
degree to which there are any dissimilarities to the patient tumors from
which they were derived and any impact that may have on the partic-
ular drug being evaluated.
In summary, we have developed preclinical cancer models of
pancreatic adenocarcinoma using patient-derived tumors. Estab-
lished models were histologically representative and highly stable
genomically, even after extensive passaging. Differences in gene
expression profiles were indicative of changes in tumor microenvi-
ronment and immune-related parameters associated with growth in
an immunocompromised host. Our analysis supports the use of
patient-derived xenografts as preclinical models for evaluating drug
response, mechanism of action, as well as biomarker identification
and validation.
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Figure W1. Mouse gDNA cross-hybridization on aCGH arrays. (A) Evaluation of cross-hybridization of mouse gDNA on human aCGH
arrays. Equal amounts of human reference gDNA (1 μg) were labeled with Cy3 and Cy5, hybridized to the aCGH arrays (right bar, 0%
mouse), and compared to 75% human/25% mouse mixture (left bar, 25% mouse). Selected chromosomes are displayed above. Addi-
tional red bands in the bars on the left side are indicative of gains (cross-hybridization). (B) Comparison of original tumor (right bar) versus
xenograft passage 4 with high mouse component (47%, left bar). Two selected chromosomes are shown, with evidence of greater
amounts of gains/amplifications in the xenograft passage with high mouse component.




Figure W3. Comparison of the number of significantly-regulated probes and number of shared probes between samples.
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